Search

Multi-Organ-on-Chip Models for Gut–Liver and Gut–Brain Axis Mechanistic Validation

Build physiologically relevant Gut–Liver and Gut–Brain microfluidic models for mechanistic validation. Our multi-organ-on-chip systems help overcome the limitations of static in vitro assays by recreating inter-organ crosstalk, barrier function, and dynamic sampling conditions. We deliver integrated datasets including TEER/permeability, inflammatory and metabolic pathway readouts, and time-resolved effluent analysis to support mechanism-focused storytelling for LBP and microbiome programs.

Overcoming the Limitations of Traditional Models

Mechanistic validation of host-microbiome interactions presents a formidable challenge for product developers. Our multi-organ-on-chip models are designed to directly address the critical shortcomings of conventional preclinical assays:

Static Model Blind Spots

Traditional 2D Transwell plates and static co-cultures lack continuous fluidic flow, shear stress, and physical inter-organ connections, failing to recreate the dynamic environment where biotherapeutics operate.

Single-Organ Limitations

Isolated single-organ models cannot explain the downstream, systemic effects of gut-derived microbial metabolites on vital secondary target organs like the liver or the brain.

Lack of Dynamic Sampling

Standard endpoint-heavy assays do not allow for continuous, real-time effluent sampling, which hinders the construction of a complete, time-resolved mechanistic chain.

By utilizing advanced microfluidic co-culture systems, we help you bypass the species-specific translation gaps of in vivo animal models and gather robust, human-relevant mechanistic data.

Typical Study Setup

We configure customizable, modular microfluidic platforms to directly address your specific research questions. A standard multi-organ-on-chip mechanistic study includes the following defined configurations:

Gut Module

Intestinal epithelial barrier (e.g., Caco-2/HT29-MTX), configured with or without an integrated mucus layer and underlying immune components.

Downstream Module

Targeted secondary tissues such as primary/immortalized liver hepatocytes (Gut-Liver) or a functional Blood-Brain Barrier/neural module (Gut-Brain).

Flow Configuration

Optimized microfluidic routing utilizing either recirculating flow for continuous crosstalk or unidirectional perfusion for sequential exposure.

Test Articles

Flexible dosing options including purified LBPs, specific microbial metabolites, complex postbiotics, or targeted inflammatory triggers (e.g., LPS).

Integrated Readouts

Continuous TEER monitoring, FITC-dextran permeability, multiplexed cytokines, key pathway biomarkers, and strategic effluent sampling for LC-MS/MS analysis.

Core Services: Target Organ Axis Modeling

We specialize in the custom development and deployment of microfluidic co-culture systems designed specifically for the mechanistic validation of microbiome therapeutics.

Gut–Liver Axis Models

The Gut-Liver axis is heavily implicated in metabolic and inflammatory diseases such as NAFLD, NASH, and ALD. Our microfluidic platforms physically and fluidically link an intestinal epithelial barrier module with a hepatic tissue module to evaluate upstream/downstream dependencies.

  • Metabolite Transport: Assess how gut-derived microbial metabolites (e.g., SCFAs, secondary bile acids) traverse the intestinal barrier and influence hepatic lipid metabolism.
  • Inflammatory Crosstalk: Support the evaluation of LPS or gut-derived inflammatory cytokines and their impact on Kupffer cell activation or hepatocyte stress.
  • Biotransformation: Can be configured to assess the step-wise metabolism of orally administered biotherapeutics across sequential organ compartments.

Gut–Brain Axis Models

Understanding the biochemical signaling between the enteric nervous system and the central nervous system is critical for neuro-psychiatric microbiome research. We connect a gut mucosal model with a Blood-Brain Barrier (BBB) or neural cell module to facilitate mechanistic testing.

  • Neurotransmitter Translocation: Supports the evaluation of microbiome-derived neurotransmitters (e.g., GABA, serotonin) and their ability to interact with the BBB model.
  • Neuroinflammation: Monitor the potential propagation of systemic inflammation from a compromised "leaky gut" module to neural tissue models.
  • Complex Co-cultures: Integrate specialized neural-epithelial co-cultures to study dedicated chemical signaling pathways induced by microbial populations.

Systemic Deliverables for Mechanistic Narratives

We don't just execute assays; we deliver comprehensive, publication-ready data packages tailored for mechanism-focused storytelling. You will receive an integrated dataset that clearly articulates the biological impact of your therapeutic candidates:

Time-course TEER and permeability datasets
Cross-compartment cytokine and metabolite profiles
Axis-specific pathway marker interpretation
High-resolution imaging and endpoint assay packages
Integrated study report formulated for mechanistic validation
Analytical Focus Supported Methodologies Relevance to Axis Research
Barrier Integrity TEER monitoring; Fluorescent Paracellular Permeability (FITC-Dextran); Confocal mapping of ZO-1 and Occludin. Essential for documenting a biotherapeutic's ability to support tight junction recovery or protect barriers from pathogen infiltration.
Inflammatory & Metabolic Pathways Multiplexed Cytokine Profiling (ELISA/Luminex array); qPCR for gene expression (e.g., TNF-α, IL-6); Lipid droplet staining. Provides objective evidence for mechanisms of action (MoA) in reducing hepatic steatosis or dampening inflammatory responses.
Dynamic Effluent Sampling Real-time media collection via microfluidic outlets; targeted/untargeted metabolomic analysis compatibility. Tracks the time-resolved journey of microbial metabolites as they are produced in the gut module and transported to secondary targets.

Project Workflow

A streamlined, client-focused process to transition your candidate from concept to validated data.

1

Study Scoping

Collaborative consultation to define the biological question, target axis, and required readouts for your program.

2

Model Configuration

Customizing the chip architecture, selecting cell lines (primary or immortalized), and finalizing flow parameters.

3

Chip Setup & Baseline

Establishing co-cultures and qualifying tissue maturity (e.g., baseline TEER) prior to test article introduction.

4

Dosing & Co-Culture

Administering the biotherapeutic or challenge agent and initiating the dynamic cross-organ interaction phase.

5

Readout Acquisition

Executing continuous sampling, endpoint imaging, and biomarker extractions according to the study protocol.

6

Interpretation & Reporting

Compiling a CRO-grade final report featuring structured datasets, mechanistic insights, and audit-ready visuals.

Why Partner With Creative Biolabs

Axis-Specific Model Design

Tailored directly for Gut-Liver and Gut-Brain mechanistic studies, ensuring your model aligns perfectly with your specific target indication and therapeutic hypothesis.

Dynamic Sampling Capabilities

Real-time effluent collection enables sophisticated time-course analysis of metabolic fluxes, moving beyond restrictive single-endpoint testing constraints.

Flexible Readout Packages

Comprehensive multi-omics integration, seamlessly bridging physical barrier assessment (TEER) with deep molecular pathway markers and cytokine profiles.

CRO-Style Reporting

We provide high-quality, actionable data packages engineered to support internal go/no-go decisions, regulatory discussions, and high-impact publications.

Published Mechanistic Validation Data on Gut-Liver Axis

Representative literature evidence demonstrates the significant capabilities of microfluidic technologies in simulating complex inter-organ communications. For instance, an integrated gut-liver-on-a-chip (iGLC) platform was successfully established in recent studies to model non-alcoholic fatty liver disease (NAFLD) pathophysiology.

By co-culturing human gut cells and liver cells under continuous fluidic flow, researchers observed how gut barrier dysfunction and gut-derived inflammatory signals could directly exacerbate hepatic lipid accumulation and fibrosis-related marker expression—dynamic insights that are challenging to acquire via traditional static models.

At Creative Biolabs, we leverage similar cutting-edge microfluidic paradigms to build custom multi-organ-on-chip solutions. This approach empowers our clients to acquire the robust mechanistic validation data necessary to confidently advance their microbiome and therapeutic candidate pipelines.

iGLC Platform Design for NAFLD Modeling. (Creative Biolabs Authorized)

Fig.1 Design of the iGLC platform to recapitulate NAFLD.1,3

Frequently Asked Questions

Our microfluidic chips incorporate continuous fluid flow to provide crucial shear stress, maintain physiological nutrient and waste gradients, and establish direct metabolic crosstalk between different organ modules (e.g., gut and liver). This dynamic environment enables the observation of systemic responses that are invisible in isolated static well plates.

Yes, our systems feature distinct microfluidic inlet and outlet ports. This architecture allows for the continuous or time-point specific sampling of effluent from specific organ compartments without breaking the sterile environment or interrupting fluidic flow, which is ideal for PK/PD and metabolomic profiling.

Absolutely. We can fully customize the readout panels to align with your specific hypothesis. For Gut-Brain axis studies, this often involves measuring specific neuro-inflammatory cytokines, evaluating the permeability of targeted metabolites, or quantifying tight junction proteins relevant to the Blood-Brain Barrier (BBB).

We successfully test a wide array of microbiome-derived materials, including purified Live Biotherapeutic Products (LBPs), complex synthetic microbial consortia, cell-free supernatants (postbiotics), and isolated microbial metabolites (e.g., SCFAs, secondary bile acids).

Other Resources

Creative Biolabs' Live Biotherapeutics - Brochure (Creative Biolabs Original)

Creative Biolabs' Live Biotherapeutics - Brochure

Probiotic Strain Products for NGP Research - Brochure (Creative Biolabs Original)

Probiotic Strain Products for NGP Research - Brochure

Custom Small-scale Probiotic Production - Brochure (Creative Biolabs Original)

Custom Small-scale Probiotic Production - Brochure

Live Biotherapeutics - Creative Biolabs - Video (Creative Biolabs Original)

Live Biotherapeutics - Creative Biolabs - Video

References

  1. Yang, Jiandong, et al. "Integrated-gut-liver-on-a-chip platform as an in vitro human model of non-alcoholic fatty liver disease." Communications Biology 6.1 (2023): 310. https://doi.org/10.1038/s42003-023-04710-8
  2. Hu, Wanlin, et al. "Microfluidic organ-on-a-chip models for the gut–liver axis: from structural mimicry to functional insights." Biomaterials science 13.7 (2025): 1624-1656. https://doi.org/10.1039/D4BM01273A
  3. Distributed under Open Access license CC BY 4.0, without modification.
Online Inquiry

For Research Use Only. Not intended for use in food manufacturing or medical procedures (diagnostics or therapeutics). Do Not Use in Humans.

Creative Biolabs-Live Biotherapeutics


ISO 9001 Certified - Creative Biolabs Quality Management System.
Contact us
Solutions

Copyright © 2026 Creative Biolabs. All Rights Reserved.

Inquiry Basket